A new proposal from the Food and Drug Administration would undermine generic availability, and put both patient safety and healthcare savings at risk.
“First, do no harm,” is a core tenant of the Hippocratic Oath taken by medical students who enter the healing profession.
Unfortunately, proposals being considered in Congress would violate that essential ethical principle.
In the valid effort to control the enormous cost of healthcare, could we be jeopardizing the very healthcare funded innovations that previously contributed to our nation’s well-being?
Unfortunately, saying you want to fix Obamacare appears to be easier than actually fixing it.
Recent reports indicate that drug shortages persist in being a significant public health threat.
Decades have come and gone, healthcare and science have become more effective and sophisticated, yet outcomes for black women have hardly budged.
The draft tax reform proposal would eliminate incentives for drug manufacturers to develop therapies to treat and cure the more than 7,000 rare diseases afflicting more than 30 million Americans.
The market restrictions that the Food and Drug Administration (FDA) places on assistive listening devices have remained mostly unchanged since the late 1970s.
Some of its members of the Dietary Guidelines Advisory Committee seem much more focused on pursuing their own environmental agendas than educating American consumers on nutrition.
Wouldn’t it make sense to ensure that Medicare patients have 24/7 access to high functioning primary care so that they won’t be forced into ERs and hospitals unnecessarily?